Related Experiment Videos
Relapse of polymyositis after prolonged remission
W Lee1, B Zimmermann, E V Lally
1Brown University School of Medicine, Roger Williams Medical Center, Providence, RI 02908, USA.
The Journal of Rheumatology
|August 1, 1997
Summary
Polymyositis patients with anti-Jo-1 antibodies can relapse after long-term remission, even after 7 years. Late relapses may be more common in antisynthetase syndrome, suggesting a need for ongoing monitoring.
Area of Science:
- Rheumatology
- Immunology
- Neurology
Background:
- Polymyositis is an idiopathic inflammatory myopathy characterized by symmetrical muscle weakness.
- Anti-Jo-1 antibodies are specific autoantibodies associated with the antisynthetase syndrome, a subset of idiopathic inflammatory myopathies.
Observation:
- A case of polymyositis with anti-Jo-1 antibodies is presented, who achieved 7 years of clinical remission.
- The patient experienced a late relapse of inflammatory muscle disease after this prolonged remission period.
Findings:
- Literature review indicates initial high-dose corticosteroid therapy achieves remission in 25-68% of polymyositis patients.
- Reported relapse rates following complete remission range from 6% to 43% in available studies.
- Late relapses after initial remission are considered unusual but potentially more frequent in antisynthetase syndrome.
Implications:
- This case highlights the possibility of late relapses in polymyositis, particularly in patients with antisynthetase syndrome.
- Extended monitoring may be warranted for patients with anti-Jo-1 antibodies even after achieving long-term remission.
- Understanding relapse patterns is crucial for optimizing long-term management strategies in inflammatory myopathies.